Brett S Carver

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/79096/publications.pdf

Version: 2024-02-01

80	10,059	109264 35	66879 78
papers	citations	h-index	g-index

83	83	83	14004
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell, 2010, 18, 11-22.	7.7	3,151
2	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	13.5	1,184
3	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell, 2011, 19, 575-586.	7.7	1,026
4	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics, 2009, 41, 619-624.	9.4	595
5	Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics, 2009, 41, 524-526.	9.4	428
6	ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine, 2013, 19, 1023-1029.	15.2	251
7	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	2.8	217
8	Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate Cancer. Journal of Urology, 2006, 176, 564-568.	0.2	212
9	Feedback Suppression of PI3KÎ± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3KÎ²2. Cancer Cell, 2015, 27, 109-122.	7.7	203
10	Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science, 2020, 368, 497-505.	6.0	165
11	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell, 2020, 38, 279-296.e9.	7.7	135
12	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nature Genetics, 2013, 45, 739-746.	9.4	134
13	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. Journal of Clinical Oncology, 2007, 25, 4365-4369.	0.8	132
14	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Journal of Experimental Medicine, 2018, 215, 159-175.	4.2	121
15	Preservation of Ejaculation in Patients Undergoing Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer. Urology, 2009, 73, 328-331.	0.5	117
16	Treatment Of Chronic Prostatitis Lowers Serum Prostate Specific Antigen. Journal of Urology, 2002, 167, 1723-1726.	0.2	115
17	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. Journal of Clinical Oncology, 2008, 26, 5524-5529.	0.8	107
18	An allelic series of miR-17â^¼92â€“mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron. Nature Genetics, 2015, 47, 766-775.	9.4	101

#	Article	IF	Citations
19	Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. Journal of Clinical Oncology, 2007, 25, 1033-1037.	0.8	99
20	ETS rearrangements and prostate cancer initiation. Nature, 2009, 457, E1-E1.	13.7	98
21	Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 2007, 25, 5603-5608.	0.8	92
22	The Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen. Journal of Urology, 2003, 169, 589-591.	0.2	83
23	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer, 2007, 109, 528-535.	2.0	73
24	Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. Journal of Urology, 2006, 176, 100-104.	0.2	70
25	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational New Drugs, 2018, 36, 458-467.	1.2	61
26	Mouse Modeling in Oncologic Preclinical and Translational Research. Clinical Cancer Research, 2006, 12, 5305-5311.	3.2	60
27	Slug regulates Eâ€cadherin repression via p19Arf in prostate tumorigenesis. Molecular Oncology, 2014, 8, 1355-1364.	2.1	51
28	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. Journal of Urology, 2014, 192, 415-419.	0.2	49
29	Germ Cell Tumors of the Testis. Annals of Surgical Oncology, 2005, 12, 871-880.	0.7	47
30	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. Urology, 2010, 75, 1431-1435.	0.5	47
31	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	47
32	The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. Journal of Urology, 2003, 169, 589-91.	0.2	47
33	African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. BJU International, 2006, 98, 783-787.	1.3	43
34	Adult and Pediatric Testicular Teratoma. Urologic Clinics of North America, 2007, 34, 245-251.	0.8	39
35	Late relapse of testicular germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 441-445.	0.8	36
36	Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU International, 2005, 95, 509-512.	1.3	32

#	Article	IF	Citations
37	Late Relapse of Testicular Germ Cell Tumors. Urologic Clinics of North America, 2015, 42, 359-368.	0.8	31
38	Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling. Molecular Cancer Therapeutics, 2015, 14, 278-288.	1.9	29
39	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. Journal of Clinical Investigation, 2020, 130, 5924-5941.	3.9	29
40	Management of post-chemotherapy extra-retroperitoneal residual masses. World Journal of Urology, 2009, 27, 489-492.	1.2	27
41	Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. Molecular and Cellular Proteomics, 2014, 13, 3082-3096.	2.5	27
42	Everolimus combined with gefitinib in patients with metastatic castrationâ€resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, 121, 3853-3861.	2.0	27
43	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer, 2010, 116, 5243-5250.	2.0	25
44	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	7.7	24
45	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer, 2008, 112, 800-805.	2.0	22
46	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. Journal of Urology, 2015, 193, 513-518.	0.2	20
47	Ureteral Injury Due to Penetrating Trauma. Southern Medical Journal, 2004, 97, 462-464.	0.3	18
48	Strategies for targeting the androgen receptor axis in prostate cancer. Drug Discovery Today, 2014, 19, 1493-1497.	3.2	18
49	Clinical stage T1c prostate cancer: Pathologic outcomes following radical prostatectomy in black and white men. Prostate, 2002, 50, 236-240.	1.2	16
50	Malignant Mesothelioma of the Tunica Vaginalis Testis: Outcomes Following Surgical Management Beyond Radical Orchiectomy. Urology, 2017, 107, 166-170.	0.5	16
51	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications, 2017, 8, 1081.	5.8	16
52	The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nature Reviews Urology, 2005, 2, 330-335.	1.4	14
53	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. Urology, 2011, 77, 368-372.	0.5	14
54	Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 29, 431-432.	7.7	14

#	Article	IF	Citations
55	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature Communications, 2021, 12, 5053.	5.8	14
56	Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Molecular Cancer Therapeutics, 2019, 18, 1577-1586.	1.9	13
57	RACE IS NOT A PREDICTOR OF PROSTATE CANCER DETECTION ON REPEAT PROSTATE BIOPSY. Journal of Urology, 2004, 172, 1853-1855.	0.2	12
58	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology, 2017, 103, 154-160.	0.5	12
59	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. Urology, 2018, 114, 133-138.	0.5	12
60	Rapid interrogation of cancer cell of origin through CRISPR editing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	12
61	The Role of Lymphadenectomy for Testicular Cancer: Indications, Controversies, and Complications. Urologic Clinics of North America, 2011, 38, 439-449.	0.8	11
62	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 2020, 38, 1332-1337.	0.8	11
63	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumorsâ€"An Update. Urology, 2011, 77, 655-659.	0.5	10
64	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. Journal of Urology, 2017, 197, 391-397.	0.2	10
65	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating Î²-Catenin Signaling. Molecular Cancer Research, 2021, 19, 573-584.	1.5	10
66	Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. BJU International, 2012, 110, 950-955.	1.3	8
67	Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer Research, 2020, 80, 1428-1437.	0.4	8
68	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. Oncologist, 2021, 26, 483-491.	1.9	8
69	Retroperitoneal Histologic Findings of Patients With Elevated Serum Alpha-fetoprotein and Pure Seminoma at Orchiectomy. Urology, 2011, 78, 844-847.	0.5	7
70	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology, 2018, 118, 114-118.	0.5	7
71	Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors. Urologic Clinics of North America, 2015, 42, 343-346.	0.8	6
72	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. Urology, 2019, 124, 174-178.	0.5	6

#	Article	IF	Citations
73	Large granular cell tumor of the penis in a 53-year-old man with coexisting prostate cancer. Urology, 2002, 59, 602.	0.5	5
74	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. Urology, 2012, 79, 1079-1084.	0.5	5
75	449: The Impact of Residual Extra-Retroperitoneal Masses in Patients with Advanced Non-Seminomatous Germ Cell Testicular Cancer. Journal of Urology, 2006, 175, 145-146.	0.2	5
76	Postchemotherapy surgery for germ cell tumors of the testis. Current Opinion in Oncology, 2011, 23, 271-274.	1.1	3
77	Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor. Indian Journal of Urology, 2010, 26, 102.	0.2	2
78	The Case for Cytoreductive Nephrectomy for the Management of Metastatic Renal Cell Carcinoma. Journal of Urology, 2009, 182, 833-834.	0.2	0
79	Editorial Comment. Journal of Urology, 2020, 204, 101-102.	0.2	0
80	Translating insights of AR signaling from mouse models. Translational Andrology and Urology, 2013, 2, 197-201.	0.6	0